TMCnet News
Dr. Andre Goy and Cota will present "Impact of Charlson Comorbidity Index (CCI) and Refining the MIPI Index in Mantle Cell Lymphoma" at 58th American Society of Hematology Annual Meeting & ExpositionSAN DIEGO, Dec. 3, 2016 /PRNewswire/ -- Dr. Andre Goy, Cota board member and President of the John Theurer Cancer Center, will present a new study utilizing real-world evidence to demonstrate the importance of comorbidities on outcomes of patients with mantle cell lymphoma at the 58th American Society of Hematology Annual Meeting & Exposition in San Diego, taking place December 3-6. Poster Presentation Information:
About Cota: Cota's technology enriches raw medical records to create research-grade data, and joins it with a suite of analysis, visualization, and management tools. This enables providers, payers, and life sciences companies to analyze, report on, and research outcomes, costs, treatments, and quality at any granularity and stage of the patient journey. The result is a constantly improving system that merges technology and science to help improve the lives of patients everywhere. Matthew Levin Logo - http://photos.prnewswire.com/prnh/20161129/443604LOGO To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/dr-andre-goy-and-cota-will-present-impact-of-charlson-comorbidity-index-cci-and-refining-the-mipi-index-in-mantle-cell-lymphoma-at-58th-american-society-of-hematology-annual-meeting--exposition-300372511.html SOURCE Cota |